China Launches 2026 Dual Drug Catalog for Innovation Access
China’s National Healthcare Security Administration (NHSA) announced on May 31 that the 2026 dual catalog adjustment for both the national medical insurance drug catalog and the commercial insurance innovative drug catalog will officially launch on June 1, introducing significant changes designed to accelerate patient access to innovative medicines while tightening safety standards for traditional remedies.
According to Xinhua News, the NHSA has released the official work plan for the adjustment, marking the second year of the “dual catalog” system first introduced in December 2025. The 2026 cycle brings a more flexible, innovation-friendly approach alongside stricter oversight of drugs lacking adequate safety data.
A Smarter Window for Drug Applications
One of the most consequential changes in the 2026 adjustment is the introduction of a “pre-application” mechanism. For this year only, drugs that have completed technical review but have not yet received formal regulatory approval can submit applications before the June 10 deadline, with the requirement to supplement their registration certificates later.
As the NHSA explained in its policy interpretation, this addresses a longstanding pain point where innovative drugs would miss the annual adjustment window due to administrative delays in the approval process. Starting in 2027, the deadline will revert to the date of the work plan’s release.
Jin Chunlin (金春林), Director of the Shanghai Health Development Research Center, told National Business Daily that the pre-application mechanism gives innovative drugs “more flexibility in terms of time windows,” improving the efficiency of getting new therapies into the payment system.
Strengthening the Bridge Between Insurance Tiers
The 2026 adjustment significantly strengthens the linkage between basic medical insurance and commercial insurance catalogs — a structural innovation that the China Pharmaceutical Innovation Association has described as a potential “transition zone” for high-priced innovative drugs.
Three new categories of off-catalog drugs are now eligible for application, including drugs already listed in the 2025 Commercial Health Insurance Innovative Drug Catalog. The inaugural 2025 catalog included 19 drugs, covering five CAR-T therapies (priced between ¥999,000 and ¥1,290,000 each), rare disease treatments, and Alzheimer’s disease drugs — products that had previously struggled to gain coverage under the basic insurance system due to cost constraints.
Jin Chunlin noted that the “revolving door mechanism” between the two catalogs has now been activated. Drugs in the commercial insurance catalog can apply for supplementary inclusion due to new indications, broadening hospital access scenarios for innovative therapies.
Tighter Safety Standards for Traditional Chinese Medicine
While expanding access for innovative drugs, the NHSA is simultaneously cracking down on traditional Chinese medicines with incomplete safety information. Drugs with “unknown” listings for contraindications, adverse reactions, or precautions — and which have not been updated within the required timeframe — will be prioritized for removal from the catalog.
This crackdown stems from the State Drug Administration’s TCM Drug Registration Management Special Provisions, effective July 1, 2023, which requires manufacturers to complete safety information within three years. The July 1, 2026 deadline is now fast approaching.
Updated Dosage Calculations and Pricing Oversight
The NHSA has also updated the standard adult body weight used for weight-based drug dosage calculations from 60kg to 65kg, reflecting data from the General Administration of Sport’s National Physical Fitness Monitoring Bulletin showing increased average body weight across the population. Body surface area calculations have been adjusted to 1.68m².
On pricing, a new coordination mechanism will align medical insurance payment standards with listed prices for bidding drugs, introducing yellow warning labels for prices exceeding 1.8 times the bidding-determined payment standard and red labels for prices exceeding 3 times.
What This Means for Patients and Industry
The 2026 dual catalog adjustment represents a maturing of China’s pharmaceutical payment policy. The NHSA is moving beyond simple cost control toward a nuanced strategy that rewards genuine innovation, creates flexible pathways for drugs nearing approval, and establishes multi-tiered payment mechanisms.
For patients, the changes promise faster access to cutting-edge therapies through both insurance channels. For pharmaceutical companies, the expanded eligibility and pre-application mechanism offer strategic opportunities — though stricter evidence requirements and pricing coordination may compress margins.
The new catalogs are expected to be published by the end of November 2026, with implementation following shortly thereafter.